Ken Griffin Evaxion Biotech A/S Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.6 - $1.17 $14,778 - $28,817
24,630 New
24,630 $16,000
Q4 2022

Feb 14, 2023
SELL
$1.7 - $30.2 $179,220 - $3.18 Million
-105,424 Reduced 98.61%
1,485 $2,000
Q3 2022

Nov 14, 2022
BUY
$1.9 - $27.7 $44,313 - $646,047
23,323 Added 27.9%
106,909 $281,000

Others Institutions Holding EVAX

# of Institutions
1
Shares Held
37.5K
Call Options Held
0
Put Options Held
0
View Full List

About Evaxion Biotech A/S

EVAX Quotes by TradingView
  • Ticker EVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,977,900
  • Market Cap $71.2M
  • Description
  • Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Ph...
More about EVAX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email